GF CSI Innovative Drugs Industry ETF(515120) rises 3.65%, with the latest net inflow of 396 million yuan

NewTimeSpace (newtimespace.com) News, as of 13:35 on July 1, 2026, GF Innovative Drug ETF (515120) rose 3.65%, with the latest price at 0.63 yuan. Over a longer time frame, as of June 30, 2026, the ETF accumulated a gain of 7.10% over the past week, ranking 2/7 among comparable funds.

In terms of liquidity, GF Innovative Drug ETF recorded an intraday turnover rate of 12.59% and a trading volume of 1.311 billion yuan, indicating active market trading. Over a longer time frame, as of June 30, the ETF's average daily trading volume over the past week reached 767 million yuan, ranking in the top 2 among comparable funds.

In terms of scale, the latest scale of GF Innovative Drug ETF reached 10.427 billion yuan, hitting a one-year high and ranking 2/7 among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of GF Innovative Drug ETF reached 17.341 billion units, hitting a one-year high and ranking 2/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net inflow for GF Innovative Drug ETF was 396 million yuan. Over a longer time frame, within the past five trading days, there were four days of net inflow, attracting a total of 528 million yuan, with an average daily net inflow of 106 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The net margin financing purchase amount of GF Innovative Drug ETF on the previous trading day reached 39.8172 million yuan, with the latest margin financing balance standing at 393 million yuan. (Data source: Wind)

As of June 30, the net value of GF Innovative Drug ETF rose by 31.52% over the past two years. From the perspective of return capability, as of June 30, 2026, since its inception, the ETF achieved a highest single-month return of 23.00%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 32.68%, and an average return of 5.48% in up months. As of June 30, 2026, the ETF's annualized excess return over its benchmark for the past three months was 2.97%.

In terms of drawdown, as of June 30, 2026, GF Innovative Drug ETF recorded a drawdown of 0.14% relative to its benchmark since the beginning of the year, reflecting lower drawdown risk among comparable funds.

In terms of fees, GF Innovative Drug ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of June 30, 2026, the two-year tracking error of GF Innovative Drug ETF was 0.026%, achieving the highest tracking accuracy among comparable funds.

It is worth noting that the valuation of the CSI Innovative Drug Industry Index, which the fund tracks, is at a historical low. The latest price-to-book (PB) ratio is 3.85x, which is lower than over 81.48% of the time in the past year, highlighting attractive valuation.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.